Recent enhancements of minimal residual disease detection by flow-cytometry in chronic lymphocytic leukemia: a study of the French CLL-MRD group

被引：0

作者：

Dahmani, Abdelmalek ^{[1
]}

Arnoulet, Christine ^{[2
]}

Baseggio, Lucile ^{[3
]}

Campos, Lydia ^{[4
]}

Chatelain, Bernard ^{[5
]}

Debliquis, Agathe ^{[6
]}

Drenou, Bernard ^{[6
]}

Jacob, Marie-Christine ^{[7
]}

Legac, Eric ^{[8
]}

Le Garff-Tavernier, Magali ^{[9
]}

Quiney, Claire ^{[9
]}

Robillard, Nelly ^{[10
]}

Solly, Francoise ^{[4
]}

Ticchioni, Michel ^{[11
]}

Cartron, Guillaume ^{[12
]}

Dartigeas, Caroline ^{[13
]}

Feugier, Pierre ^{[14
]}

Leblond, Veronique ^{[15
]}

Lepretre, Stephane ^{[15
]}

Van den Neste, Eric ^{[16
]}

Delfau-Larue, Marie-Helene ^{[17
]}

Cymbalista, Florence ^{[1
]}

Letestu, Remi ^{[1
]}

机构：

[1] Univ Paris 13, Hop Avicenne, AP HP, Bobigny, France

[2] CLCC IPC, Marseille, France

[3] CHU Pierre Benite, Lyon, France

[4] CHU St Priest En Jarez, St Etienne, France

[5] UCL Mont Godinne, Yvoir, France

[6] CH E Muller, Mulhouse, France

[7] EFS, Grenoble, France

[8] CHR Source, Orleans, France

[9] Hop La Pitie Salpetriere, Paris, France

[10] CHU Nantes, Nantes, France

[11] Hop Archet, Nice, France

[12] CHU Montpellier, Montpellier, France

[13] CHU Tours, Tours, France

[14] CHU Nancy, Nancy, France

[15] Ctr Henri Becquerel, F-76038 Rouen, France

[16] UCL St Luc, Brussels, Belgium

[17] CHU Henri Mondor, F-94010 Creteil, France

来源：

LEUKEMIA & LYMPHOMA | 2015年 / 56卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

138

引用

页码：115 / 116

页数：2

共 50 条

[31] Performance of a novel 8-color flow cytometry panel in the detection of minimal residual disease assessment of chronic lymphocytic leukemia
Wu, Yujie
Chen, Xiao
Zhao, Sishu
Shi, Yu
Zhang, Ninghan
Guo, Zhen
Qiao, Chun
Jin, Huimin
Zhu, Liying
Zhu, Huayuan
Li, Jianyong
LEUKEMIA & LYMPHOMA, 2023, 64 : S104 - S105
[32] Assessment of Minimal Residual Disease (MRD) in Chronic Lymphocytic Leukemia: A Review of the Data and Future Directions
Mato, Anthony R.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (06) : 7 - 14
[33] Flow cytometry in acute myeloid leukemia and detection of minimal residual disease
Cai, Qihui
Lan, Haiqiang
Yi, Deng
Xian, Bojun
Zidan, Luo
Li, Jianqiao
Liao, Zhaohong
CLINICA CHIMICA ACTA, 2025, 564
[34] The Evolving Use of Minimal Residual Disease (MRD) Assessment in Chronic Lymphocytic Leukemia: Q&A
Cheson, Bruce D.
Mato, Anthony R.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (06) : 15 - 20
[35] Statistical validation of a threshold to discriminate flow-cytometry minimal residual disease (MRD) levels with prognostic significance in acute myeloid leukemia (AML).
Buccisano, Francesco
Maurillo, Luca
Gattei, Valter
Del Poeta, Giovanni
Del Principe, Maria Ilaria
Panetta, Paola
Fraboni, Daniela
Consalvo, Maria Irno
Ottaviani, Licia
Renzi, Daniela
Faccia, Sabrina
Sarlo, Chiara
Lo Coco, Francesco
Amadori, Sergio
Venditti, Adriano
BLOOD, 2006, 108 (11) : 651A - 652A
[36] Minimal residual disease (MRD) in hairy cell leukemia (HCL):: Comparative detection by flow cytometry (FC) and immunohistochemistry (IHC).
Sarmiento, M
Scolnik, M
Narbaitz, M
Bengió, R
BLOOD, 1999, 94 (10) : 284A - 284A
[37] Routine monitoring of minimal residual disease by flow cytometry in adult acute lymphocytic leukemia
Huh, YO
Lee, JN
Cooper, D
Kantarjian, H
Pierce, S
Thomas, D
CYTOMETRY PART A, 2004, 59A (01): : 81 - 81
[38] CD160: a novel approach to minimal residual disease (MRD) assessment in chronic lymphocytic leukaemia (CLL)
Farren, T. W.
Liu, F.
Macey, M. G.
Jenner, M.
Prentice, A.
Nathwani, A.
Agrawal, S. G.
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 : 72 - 72
[39] Clinical significance of minimal residual disease (MRD), as assessed by different techniques, after stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL)
Moreno, C
Villamor, N
Esteve, J
Colomer, D
Bosch, F
Carnpo, E
Montserrat, E
BLOOD, 2005, 106 (11) : 571A - 571A
[40] Patterns of graft-versus-leukemia-mediated minimal residual disease (MRD) eradication in patients allografted for poor-risk chronic lymphocytic leukemia (CLL)
Hahn, M.
Boettcher, S.
Dietrich, S.
Herth, I.
Hegenbart, U.
Rieger, M.
Stadtherr, P.
Bondong, A.
Ritgen, M.
Zenz, T.
Kneba, M.
Ho, A. D.
Dreger, P.
ONKOLOGIE, 2013, 36 : 58 - 58

← 1 2 3 4 5 →